Prosecution Insights
Last updated: July 17, 2026
Application No. 18/576,582

ENTERAL NUTRIENT PREPARATION

Non-Final OA §102
Filed
Jan 04, 2024
Priority
Jul 08, 2021 — JP 2021-113534 +1 more
Examiner
O'HERN, BRENT T
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Otsuka Pharmaceutical Co., Ltd.
OA Round
1 (Non-Final)
78%
Grant Probability
Favorable
1-2
OA Rounds
2m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allowance Rate
1056 granted / 1355 resolved
+17.9% vs TC avg
Strong +20% interview lift
Without
With
+20.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
54 currently pending
Career history
1392
Total Applications
across all art units

Statute-Specific Performance

§101
0.3%
-39.7% vs TC avg
§103
68.7%
+28.7% vs TC avg
§102
5.3%
-34.7% vs TC avg
§112
17.6%
-22.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1355 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group II in the reply filed on 6/18/2026 is acknowledged. Specification The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the applicant’s use. Arrangement of the Specification As provided in 37 CFR 1.77(b), the specification of a utility application should include the following sections in order. Each of the lettered items should appear in upper case, without underlining or bold type, as a section heading. If no text follows the section heading, the phrase “Not Applicable” should follow the section heading: (a) TITLE OF THE INVENTION. (b) CROSS-REFERENCE TO RELATED APPLICATIONS. (c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT. (d) THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT. (e) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A READ-ONLY OPTICAL DISC, AS A TEXT FILE OR AN XML FILE VIA THE PATENT ELECTRONIC SYSTEM. (f) STATEMENT REGARDING PRIOR DISCLOSURES BY THE INVENTOR OR A JOINT INVENTOR. (g) BACKGROUND OF THE INVENTION. (1) Field of the Invention. (2) Description of Related Art including information disclosed under 37 CFR 1.97 and 1.98. (h) BRIEF SUMMARY OF THE INVENTION. (i) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S). (j) DETAILED DESCRIPTION OF THE INVENTION. (k) CLAIM OR CLAIMS (commencing on a separate sheet). (l) ABSTRACT OF THE DISCLOSURE (commencing on a separate sheet). (m) SEQUENCE LISTING. (See MPEP § 2422.03 and 37 CFR 1.821 - 1.825). A “Sequence Listing” is required on paper if the application discloses a nucleotide or amino acid sequence as defined in 37 CFR 1.821(a) and if the required “Sequence Listing” is not submitted as an electronic document either on read-only optical disc or as a text file via the patent electronic system. When there are drawings, there shall be a “brief description of the several views of the drawings” (See 37 C.F.R. 1.74.). The section heading “brief description of the several views of the drawings” as set forth in 37 C.F.R. 1.74 is missing. Please correct. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim 8 is/are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Isaji (JP 2014003960). Regarding Claim 8, Isaji (‘960) teaches a method for providing nutritional supplementation to a subject in poor nutrition state using an enteral nutrient preparation (See Abs., p. 1, Example 8-1, claims.), the enteral nutrient preparation comprising protein and a lipid, and an amino acid as necessary (See Abs., p. 1, Example 8-1, claims.), wherein 90 wt% or more of the protein is not milk-derived protein (See p. 4, l. 31+, p. 11, l. 4+ 100% protein derived from vegetable and collagen protein.), and (a) an amino acid score of a mixture of the protein and the amino acid is 100, and a lipid calorie ratio is 40% or more (See Table 17, p. 7, l. 38+ and claims where the amino acid score is 100 and the lipid calorie ratio is 46%.). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRENT T O'HERN whose telephone number is (571)272-6385. The examiner can normally be reached M-Th 5:00 am - 3:30 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Emily Le can be reached at 571-272-0903. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRENT T O'HERN/ Primary Examiner, Art Unit 1793 June 23, 2026
Read full office action

Prosecution Timeline

Jan 04, 2024
Application Filed
Jul 01, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12667114
METHOD FOR PRODUCING POWDERED OIL AND/OR FAT COMPOSITION
2y 10m to grant Granted Jun 30, 2026
Patent 12648580
Scalable Methods for Manufacturing Alternative Meat Cuts
2y 9m to grant Granted Jun 09, 2026
Patent 12635716
DRINKABLE EGG WHITE
3y 5m to grant Granted May 26, 2026
Patent 12635703
DAIRY-LIKE COMPOSITIONS AND RELATED METHODS
2y 10m to grant Granted May 26, 2026
Patent 12628850
ENZYMATICALLY STABILIZED PASTA STRUCTURE AND METHOD OF PREPARING THE SAME
3y 2m to grant Granted May 19, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
78%
Grant Probability
98%
With Interview (+20.5%)
2y 8m (~2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1355 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month